We are thrilled to announce that Global Clinical Trials (GCT) has been selected to conduct a clinical trial in schizophrenia across multiple European Union countries.
The study is a double-blinded, randomized, placebo-controlled, adaptive Phase IIb trial, focused to evaluate the IMP efficacy throughout negative symptoms and cognitive impairment, associated to schizophrenia.
This trial targets 2 of the most debilitating and unmet symptoms, dominated in schizophrenia: negative symptoms and cognitive dysfunctions, offering hope to therapeutic innovation, where it is mostly needed.
This award reflects Sponsor’s confidence to GCT’s deep expertise, conducting clinical trials and EU regulatory insights in a field of neuropsychiatric trials.
We are proud to assist Sponsor in its efforts to advance novel treatment for patients.